{"gene":"EPOR","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":2009,"finding":"Epo-induced endocytosis of EpoR occurs via clathrin-mediated endocytosis. Both JAK2 kinase activity and EpoR cytoplasmic tyrosines (Y429, Y431, Y479) are required for ligand-dependent EpoR internalization. Phosphorylated Y429, Y431, and Y479 bind the p85 subunit of PI3K upon Epo stimulation, and p85α/β recruit endocytic machinery in a PI3K activity-independent manner. Truncated EpoRs from PFCP patients lacking these tyrosines fail to bind p85 or internalize upon stimulation.","method":"Mutagenesis of EpoR cytoplasmic tyrosines, knockdown of p85α/p85β with dominant-negative constructs, clathrin inhibition assays, analysis of PFCP patient receptor mutants","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro mutagenesis combined with multiple orthogonal methods (knockdown, dominant negatives, patient mutant analysis) in a single rigorous study","pmids":["19336760"],"is_preprint":false},{"year":2013,"finding":"Epo induces Cbl-dependent ubiquitination of the p85 regulatory subunit of PI3K, which is bound to phosphotyrosines on EpoR. Ubiquitinated p85 interacts with endocytic protein epsin-1, driving EpoR endocytosis. Knockdown of Cbl or expression of epsin-1 mutants lacking ubiquitin-interacting motifs impairs EpoR internalization. PFCP-mimicking EpoR mutants cannot bind p85, co-localize with epsin-1, or internalize, causing Epo hypersensitivity. Restoring p85 binding to PFCP receptors rescues epsin-1 co-localization and EpoR internalization.","method":"Cbl knockdown, dominant-negative Cbl expression, epsin-1 UIM mutants, co-localization assays, primary erythroid progenitor knockdown, rescue experiments with restored p85-binding EpoR","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — multiple orthogonal methods (knockdown, dominant negatives, mutagenesis, rescue) in a single rigorous study establishing a novel pathway","pmids":["24113870"],"is_preprint":false},{"year":2008,"finding":"EPO regulates hepcidin expression in a dose-dependent manner in hepatocytes through EPOR signaling. This is mediated through the transcription factor C/EBPα: EPO treatment decreases C/EBPα binding to the hepcidin promoter, as shown by chromatin immunoprecipitation. Pre-treatment with an EPOR-blocking antibody restores hepcidin mRNA levels, confirming EPOR dependence.","method":"Anti-EPOR blocking antibody, chromatin immunoprecipitation (ChIP) for C/EBPα at the hepcidin promoter, RT-PCR/Western blot for C/EBPα, freshly isolated mouse hepatocytes and HepG2 cells","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal functional blocking antibody plus ChIP, single lab with two orthogonal methods","pmids":["18326822"],"is_preprint":false},{"year":2008,"finding":"Constitutively activated Stat5a (cS5) is sufficient to rescue erythroid proliferation in both Jak2−/− and EpoR−/− cells in an Epo-independent manner, and tamoxifen-induced DNA binding of a Stat5a-ER fusion construct enables erythropoiesis in the absence of Epo. This places activated Stat5 as a critical downstream effector of Jak2 in erythropoiesis, functionally downstream of EpoR.","method":"Genetic rescue with constitutively active Stat5a mutant in Jak2−/− and EpoR−/− fetal liver cells, tamoxifen-inducible Stat5a-ER construct, fetal liver transplantation into irradiated mice","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — epistasis by genetic rescue with multiple complementary approaches (cS5 in KO cells, inducible system, transplantation), rigorous in vivo validation","pmids":["18239084"],"is_preprint":false},{"year":2001,"finding":"Stat5 and PI3K signaling pathways are utilized by both EpoR/c-Kit and v/c-ErbB in erythroid progenitor expansion. v-ErbB-transformed cells and normal progenitors depend on PI3K signaling for renewal, establishing that EpoR-driven PI3K signaling is essential for erythroid progenitor renewal.","method":"Immortalized erythroid progenitor lines from p53−/− fetal livers, ErbB inhibition, inhibition of Stat5 and PI3K, comparison with EpoR/c-Kit–driven expansion","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition plus genetic cell lines, single lab","pmids":["11439328"],"is_preprint":false},{"year":2001,"finding":"EpoR expression and activation regulate the timing of the definitive wave of erythropoiesis. A constitutively active form of EpoR (R129C EpoR) knocked into mice leads to earlier onset of definitive erythropoiesis in the yolk sac, demonstrating that EpoR signaling activation is sufficient to advance the developmental switch between primitive and definitive erythropoiesis.","method":"Knock-in mouse model with constitutively active EpoR-R129C, spatial/temporal analysis of Epo and EpoR gene expression during embryogenesis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic knock-in with defined developmental phenotypic readout, establishing EpoR as a direct regulator of erythroid wave timing","pmids":["11520789"],"is_preprint":false},{"year":1998,"finding":"The prolactin receptor (PrlR) can fully replace EpoR in supporting terminal differentiation of EpoR−/− erythroid progenitors, demonstrating that EpoR has no instructive or unique signaling role in red blood cell differentiation beyond generic cytokine receptor signaling. Additionally, the synergistic interaction between EpoR and c-Kit is fully reproduced by PrlR and c-Kit, showing no requirement for an EpoR-unique signal in this synergism.","method":"Retroviral transduction of PrlR and PrlR/EpoR chimera into EpoR−/− progenitors, in vitro differentiation assays with prolactin and stem cell factor","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic rescue experiment with EpoR−/− cells using chimeric receptors, multiple readouts, directly testing instructive vs. permissive signaling","pmids":["9716574"],"is_preprint":false},{"year":1997,"finding":"EPO activates the Raf1/MEK/MAP kinase pathway independently of Shc phosphorylation in CTLL-EPO-R cells. While IL-2 and IL-15 stimulate Shc tyrosine phosphorylation, EPO does not activate Shc but instead activates Raf1 and ERK2 through Shp2/Grb2/receptor complexes, establishing an Shc-independent Raf1 activation pathway downstream of EpoR.","method":"Stimulation of CTLL-EPO-R cells with EPO/IL-2/IL-15, immunoprecipitation of Shc and Shp2, Raf1 kinase assay, ERK2 kinase assay","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro kinase assays and co-immunoprecipitation, single lab with two orthogonal methods","pmids":["8978277"],"is_preprint":false},{"year":2002,"finding":"SOCS1, SOCS2, SOCS3, and CIS induction by EPO depends on Stat5 but not on MAPK or PI3K. SOCS1, SOCS3, and CIS overexpression negatively regulate EPO-mediated cell proliferation and Stat5 phosphorylation; SOCS2 is less effective; SOCS4 is ineffective. These results establish differential roles of SOCS family members downstream of EPOR signaling.","method":"Inhibition of specific signaling molecules (Stat5, MAPK, PI3K), EpoR mutant cell lines activating only subsets of signaling cascades, stable inducible SOCS overexpression cell lines, luciferase reporter assays","journal":"Journal of interferon & cytokine research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two independent experimental approaches (signaling inhibitors plus EpoR mutant lines) in a single lab","pmids":["12396724"],"is_preprint":false},{"year":2006,"finding":"Functional EpoR, Stat5, and glucocorticoid receptor (GR) are each cell-autonomously required for erythroblast renewal in vitro. Cells from EpoR-H mutant mice show enhanced differentiation instead of renewal. Additionally, Stat5ab is required for Epo-induced terminal differentiation: Stat5ab−/− differentiating erythroblasts undergo apoptosis due to absent Bcl-XL induction, a defect fully rescued by exogenous Bcl-XL.","method":"Primary erythroblast cultures from EpoRH, GRdim/dim, and Stat5ab−/− mice; retroviral Bcl-XL rescue; proliferation and differentiation assays","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic mutant mouse lines with rescue experiment, establishing cell-autonomous pathway requirements with defined molecular mechanism","pmids":["16407844"],"is_preprint":false},{"year":2003,"finding":"SLAP (Src-like adaptor protein) forms a specific complex with EpoR in FLI-1-transformed erythroblasts. Constitutive SLAP expression severely impairs Epo-induced erythroid differentiation by inhibiting STAT5 activation and Bcl-X gene upregulation downstream of EpoR, establishing SLAP as a negative regulator of EpoR signaling.","method":"Co-immunoprecipitation of SLAP with EpoR, stable SLAP expression in primary erythroblasts, STAT5 phosphorylation assays, hemoglobinization assays","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — co-IP establishing complex plus functional overexpression with specific signaling readouts, single lab","pmids":["12946994"],"is_preprint":false},{"year":2012,"finding":"EpoR signaling increases red cell size (MCV) while also increasing the number and speed of erythroblast cell cycles. EpoR-regulation of cell size is independent of iron-based size regulation. High EPO increases MCV in wild-type mice and human volunteers, and this effect outlasts EPO treatment duration.","method":"EpoR−/− erythroblasts with survival rescue signaling, comparison of cycling parameters, EPO injection in wild-type mice and human volunteers, MCV measurements","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — EpoR−/− genetic system plus in vivo mouse and human data, multiple orthogonal readouts","pmids":["34921133"],"is_preprint":false},{"year":2012,"finding":"JAK2V617F activates Lu/BCAM-mediated red cell adhesion through an EpoR-independent Rap1/Akt signaling pathway. Knockdown of EpoR in HEL cells does not alter Akt activity or cell adhesion to laminin, establishing that this JAK2V617F-driven pathway is distinct from EpoR.","method":"EpoR knockdown in HEL cells, dominant-negative Rap1S17N expression, Rap1 inhibitor GGTI-298, phospho-Akt measurement, laminin adhesion assays","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown plus pharmacological inhibition and dominant-negative approaches, single lab","pmids":["23160466"],"is_preprint":false},{"year":2012,"finding":"EPOR-regulated transcriptome analysis in primary CFU-e progenitors identified 160 EPO/EPOR target transcripts. SOCS2, Socs3, Spred1, Spred2, and Eaf1 serve as negative-feedback components. The atypical TNF-receptor Tnfr-sf13c is upregulated >5-fold by EPO via EPOR/Jak2/Stat5 and promotes proerythroblast survival and erythroblast formation.","method":"Global transcriptome analysis of primary bone marrow CFU-e progenitors, Tnfr-sf13c ligation survival assays, identification of EPOR/Jak2/Stat5 response genes","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcriptome screen plus functional validation of Tnfr-sf13c in survival assays, single lab","pmids":["22808010"],"is_preprint":false},{"year":2012,"finding":"Spry1 is selectively expressed in CFU-e to erythroblast stages and is phosphorylated at its conserved PY53 motif by EpoR signaling upon EPO stimulation (discovered by LC-MS/MS). Conditional Spry1 deletion leads to hyperactivation of Erk1/2 and Jak2 in erythroid progenitors, identifying Spry1 as a negative feedback regulator and candidate suppressor of Jak2 downstream of EpoR.","method":"Mx1-Cre conditional Spry1 deletion, LC-MS/MS phosphoproteomic discovery of Spry1-PY53, signaling analysis in Spry1-null progenitors, anemia challenge models","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — MS-based phosphosite discovery plus in vivo genetic deletion with defined signaling phenotype, single lab with multiple orthogonal methods","pmids":["22508938"],"is_preprint":false},{"year":2020,"finding":"PTPN18, identified by phospho-tyrosine PTM proteomics as a novel EPO target (phosphorylated at Y389 in a JAK2-dependent manner), promotes EPO-dependent hematopoietic cell proliferation and survival. PTPN18 sustains EPO-induced activation of ERK1/2, AKT, STAT5, and JAK2. It also increases high-molecular-weight EPOR forms while inhibiting EPO-induced phosphorylation of the EPOR-associated adaptor RHEX at Y141. Each effect depends on PTPN18-Y389.","method":"Phospho-tyrosine PTM proteomics, ectopic PTPN18 expression, JAK2 inhibitor treatment, RHEX phosphorylation assays, cell proliferation/survival assays, EPOR molecular weight analysis","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — proteomics discovery plus mutagenesis and functional assays, single lab","pmids":["32027948"],"is_preprint":false},{"year":2016,"finding":"CIS interacts with phosphorylated EpoR at Y401, which is critical for STAT5 and ERK activation. The SH2 domain and tyrosine phosphorylation of CIS at Y253 are required for its tumor-suppressive anti-proliferative effects in JAK2V617F-transformed cells. CIS knockdown enhances STAT5 and ERK activation in JAK2V617F cells; CIS overexpression suppresses these signals and inhibits tumor formation.","method":"CIS-EpoR co-immunoprecipitation at Y401, CIS RNA interference, CIS overexpression with SH2 domain mutants, STAT5/ERK phosphorylation assays, nude mouse tumor formation assay","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP at specific phosphotyrosine plus mutagenesis and functional rescue assays, single lab","pmids":["28038963"],"is_preprint":false},{"year":2003,"finding":"Non-tyrosine-containing sequences in the membrane-proximal region of EPOR elicit an important Stat5-dependent cell survival signal in 32D cells, independently of EpoR cytoplasmic tyrosines. This survival signal is serum-independent, revealing a previously unrecognized Stat5-dependent survival pathway in the EPOR cytoplasmic region.","method":"Stable transfection of 32D cells with wild-type and tyrosine-null EPOR mutants, dominant-inhibitory Stat5 isoform expression, EPO-dependent survival and proliferation assays","journal":"Experimental hematology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis combined with dominant-negative Stat5, single lab, multiple receptor mutants tested","pmids":["14662339"],"is_preprint":false},{"year":2008,"finding":"KIT-associated intracellular tyrosines, particularly those binding Src kinases, are required for EpoR co-signaling. EpoR-Y343 is the single most important EpoR tyrosine for proliferation cooperativity with KIT, inducing Stat5, PI3K/Akt, and Erk1/2 activation. Restoration of the PLC-γ binding site in KIT antagonizes co-signaling with EpoR, while the Src binding sites are sufficient for restoring KIT–EpoR co-signaling.","method":"Co-expression of KIT and EpoR tyrosine-to-phenylalanine mutants in 32D cells, proliferation assays, STAT5/Akt/ERK phosphorylation analysis","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic mutagenesis of EpoR and KIT tyrosines with functional readouts, single lab","pmids":["18538998"],"is_preprint":false},{"year":2014,"finding":"PFCP-associated EPOR mutations (deletion Del1377-1411, nonsense C1370A, missense G1445A) cause slower receptor degradation, higher levels of glycan-mature receptor forms, increased sensitivity to low ligand concentrations, and extended downstream signaling cascades, as studied using EGFR–EPOR chimeric receptors. These mechanisms explain Epo hypersensitivity in PFCP patients.","method":"EGFR–EPOR chimeric receptor system activated by EGF binding, Western blot for receptor glycosylation/degradation, signaling duration assays","journal":"British journal of haematology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — chimeric receptor system with defined mutations, multiple biochemical readouts, single lab","pmids":["24533580"],"is_preprint":false},{"year":2021,"finding":"EpoR in osteoprogenitor cells (EpoR:Osx-cre conditional knockout) is required for normal bone homeostasis and for EPO-induced bone loss. Deletion of EpoR in osteoprogenitors reduced the RANKL/OPG ratio, decreased osteoblast-supported osteoclastogenesis, and protected female mice from EPO-induced trabecular bone loss and increased osteoclast numbers. This demonstrates that EpoR in osteoprogenitors regulates osteoblast function and osteoblast-mediated osteoclastogenesis.","method":"EpoR:Osx-cre conditional knockout mice, histomorphometry, serum bone markers (P1NP, osteocalcin, TRAP), osteoblast/osteoclast co-culture from cKO vs. control, EPO pump implantation","journal":"Bone research","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional genetic deletion with multiple in vivo and ex vivo readouts, co-culture mechanistic validation, and rescue by EPO challenge in a single rigorous study","pmids":["34518518"],"is_preprint":false},{"year":1993,"finding":"SFFV gp52 env protein forms an immunoprecipitable complex with EpoR in the endoplasmic reticulum. However, formation of this ER complex is not sufficient for either mitogenicity in cell culture or pathogenicity in mice; instead, processing of gp52 to more highly glycosylated forms is required for EpoR-dependent mitogenicity and splenomegaly.","method":"Glycosylation site mutants of SFFV env, co-immunoprecipitation of gp52 with EpoR, BaF3-epoR cell mitogenicity assays, mouse splenomegaly model","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus mutagenesis plus functional and in vivo assays, single lab, multiple orthogonal methods","pmids":["8437218"],"is_preprint":false},{"year":1993,"finding":"Six monoclonal antibodies (MoAbs) to the extracellular domain of human EpoR were generated. Four neutralizing (Group I) MoAbs compete with radiolabeled EPO for EpoR binding and inhibit EPO-dependent cell growth, identifying the EPO-binding epitope region. Two non-neutralizing MoAbs recognize discrete epitopes that do not overlap the EPO-binding site.","method":"Monoclonal antibody generation, immunoprecipitation of 35S-labeled EpoR, radiolabeled EPO competition binding assay, EPO-dependent Ba/F3-hEPO-R growth inhibition","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — competition binding plus functional neutralization assays, single lab defining ligand-binding epitope","pmids":["7686789"],"is_preprint":false},{"year":2012,"finding":"EPOR undergoes sharply ligand-dependent inward trafficking in UT7epo cells and primary proerythroblasts. EPOR-68K is a core-glycosylated intracellular pool and EPOR-70K comprises the apparent cell-surface EPOR population. Polycythemia-associated C-terminal truncated EPOR-T alleles are persistently activated upon EPO challenge, become over-represented during exponential growth, and result in EPO dose-dependent loss of endogenous wild-type EPOR through squelching of C-terminal-mediated negative feedback.","method":"Novel rabbit monoclonal antibodies to intracellular, phospho-activated, and extracellular EPOR domains; Brefeldin A treatment; N-glycanase digestion; Western blot analysis of EPOR forms; UT7epo and primary proerythroblast trafficking assays; expression of PFCP EPOR-T mutants","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal biochemical methods with validated reagents, single lab","pmids":["22253704"],"is_preprint":false},{"year":2021,"finding":"EpoR is expressed in erythroblastic island (EBI) macrophages (defined by tdTomato reporter in EpoR-tdTomato-Cre mice), as well as in subsets of hematopoietic stem cells, progenitors, megakaryocytes, B cells, spleen red pulp macrophages, and liver Kupffer cells. EPO injection selectively promotes proliferation of EpoR-expressing cells and induces erythroid lineage bias in hematopoiesis.","method":"EpoR-tdTomato-Cre knock-in reporter mouse, Cre-mediated floxed STOP excision validation, flow cytometry, EPO injection experiments","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic reporter mouse with Cre-mediated validation plus functional EPO injection experiments, single lab with multiple orthogonal approaches","pmids":["34098576"],"is_preprint":false},{"year":2022,"finding":"EpoR signaling in the monocytic/osteoclast lineage contributes to EPO-induced bone loss. Conditional deletion of EPOR in the monocytic lineage using LysMCre significantly reduced the high-dose EPO-induced increase in bone marrow preosteoclasts (CD115+) and the resulting trabecular bone loss in female mice, without interfering with erythropoiesis.","method":"LysMCre EPOR conditional knockout mice, Cx3cr1Cre EPOR conditional knockout mice, high- and low-dose EPO administration, flow cytometry for CD115+ preosteoclasts, microCT bone volume measurements","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two independent Cre-driver conditional KO models, in vivo EPO challenge, single lab","pmids":["36233351"],"is_preprint":false},{"year":2023,"finding":"EpoR activation leads to immediate Jak2-dependent phosphorylation of the CDK inhibitor p27Kip1 at tyrosine 88 (Y88), converting it from a CDK inhibitor to an activator/assembly factor of CDK4/6, thereby promoting erythroid progenitor proliferation. Knock-in mice with p27Y88F mutation exhibit lower red blood cell counts, lower hematocrit, and reduced CFU-E colony outgrowth.","method":"Co-immunoprecipitation of p27 with EpoR, p27-Y88 phosphorylation assays in presence of Jak2 inhibitor, p27Y88F knock-in mice, CFU-E colony assays, complete blood count analysis","journal":"Cells","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — direct binding assay, site-specific phosphorylation with Jak2 inhibitor validation, and in vivo knock-in genetic model with defined erythroid phenotype","pmids":["37443738"],"is_preprint":false},{"year":2024,"finding":"EPO regulates energy metabolism through the EPO-EpoR-RUNX1 axis. EpoR in white adipose tissue mediates metabolic activity; male mice with adipose-specific EpoR ablation show increased fat mass and obesity susceptibility. EPO treatment increases RUNX1 protein in adipose tissue by decreasing FBXW7 ubiquitin ligase expression, thereby stabilizing RUNX1, which directly inhibits lipogenic gene expression. This effect is absent in adipose-specific EpoR knockout mice.","method":"Adipose-specific EpoR knockout mice, EPO treatment of wild-type vs. knockout mice, RUNX1 protein stability assays, FBXW7 expression analysis, lipogenic gene expression profiling","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — tissue-specific conditional KO plus mechanistic dissection of FBXW7-RUNX1 axis, multiple in vivo and molecular readouts in single rigorous study","pmids":["39284834"],"is_preprint":false},{"year":1999,"finding":"A truncated form of human EPO receptor (EPOR-T) acts as a dominant negative regulator of EPO-induced erythroid differentiation. EPOR-T transfection in UT-7/GM cells induces apoptosis in the presence of EPO and blocks EPO-induced erythroid differentiation and hemoglobinization. EPOR-T is expressed in 7/9 myelodysplastic syndrome cases but not in normal controls, suggesting it may contribute to ineffective erythropoiesis in MDS.","method":"Stable transfection of EPOR-T in UT-7/GM cells, EPO-dependent hemoglobinization assay, apoptosis assay, RT-PCR in MDS patient samples","journal":"Experimental hematology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional transfection with apoptosis and differentiation readouts plus patient sample analysis, single lab","pmids":["10029161"],"is_preprint":false},{"year":2021,"finding":"Extracellular CIRP (eCIRP) reduces macrophage surface EPOR levels by impairing Rab26, a member of the Ras family of small G proteins that controls EPOR transport to the cell surface. Impaired Rab26 reduces surface EPOR, which restrains EPOR-mediated M2 macrophage polarization. EPO treatment fails to promote M2 polarization in Rab26 knockout macrophages, establishing Rab26 as required for EPOR surface expression and downstream macrophage polarization signaling.","method":"Myeloid-specific EPOR-deficient mice, Rab26 knockout macrophages, eCIRP treatment, flow cytometry for surface EPOR, macrophage polarization assays, LPS-induced ALI model","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO models for both EPOR and Rab26 with functional rescue assays, single lab","pmids":["34925338"],"is_preprint":false}],"current_model":"EPOR is a cytokine receptor that, upon EPO binding, recruits and activates JAK2, leading to phosphorylation of specific intracellular tyrosines (including Y343, Y401, Y429, Y431, Y479) that serve as docking sites for signaling adaptors (p85/PI3K, Grb2/Shp2, CIS) to activate STAT5, PI3K/AKT, and RAS/ERK pathways; STAT5 is the critical downstream effector for erythroid survival and differentiation (inducing Bcl-XL), while ligand-induced clathrin-mediated endocytosis terminates signaling through a p85 ubiquitination/Cbl/epsin-1 mechanism; truncating PFCP mutations in the EPOR C-terminus impair this endocytic negative feedback, causing Epo hypersensitivity; beyond erythropoiesis, EpoR is functionally expressed in osteoprogenitors, adipose tissue, macrophages, and other cell types where it regulates bone homeostasis, energy metabolism, and immune polarization through the same core JAK2/STAT pathway."},"narrative":{"mechanistic_narrative":"EPOR is the erythropoietin receptor, a cytokine receptor that converts EPO binding into a JAK2-driven signaling program controlling erythroid progenitor survival, proliferation, and differentiation [PMID:18239084, PMID:16407844]. Upon stimulation, JAK2 phosphorylates EPOR cytoplasmic tyrosines that nucleate distinct effector arms: STAT5 activation is the critical downstream node for erythropoiesis, and constitutively active STAT5 alone rescues proliferation of both Jak2-/- and EpoR-/- cells, while Stat5-dependent induction of Bcl-XL prevents erythroblast apoptosis during terminal differentiation [PMID:18239084, PMID:16407844]. EPOR also drives Shc-independent Raf1/MEK/ERK activation via Shp2/Grb2 and a PI3K arm required for progenitor renewal [PMID:8978277, PMID:11439328]. Phosphorylated Y429/Y431/Y479 recruit the p85 subunit of PI3K, which—after Cbl-dependent ubiquitination and engagement of epsin-1—drives clathrin-mediated endocytosis that terminates signaling; C-terminal truncating mutations underlying primary familial and congenital polycythemia (PFCP) abolish p85 binding and internalization, causing EPO hypersensitivity and persistent receptor activation [PMID:19336760, PMID:24113870, PMID:24533580, PMID:22253704]. Signal magnitude is further constrained by a layered negative-feedback network including STAT5-induced SOCS/CIS proteins and Sprouty/Spred regulators that dampen JAK2 and ERK [PMID:12396724, PMID:28038963, PMID:22508938, PMID:22808010]. Beyond erythropoiesis, EpoR is functionally expressed and signals through the same axis in osteoprogenitors and the monocytic lineage to regulate bone homeostasis [PMID:34518518, PMID:36233351], in white adipose tissue via an EpoR-RUNX1 axis controlling energy metabolism [PMID:39284834], and in macrophages where surface receptor levels gate M2 polarization [PMID:34925338].","teleology":[{"year":1993,"claim":"Defining the EPO-binding region of the receptor established which extracellular epitopes mediate ligand engagement and could neutralize signaling.","evidence":"Monoclonal antibodies against the human EpoR extracellular domain tested in EPO competition binding and growth-inhibition assays","pmids":["7686789"],"confidence":"Medium","gaps":["No atomic structure of the EPO-EPOR complex resolved here","Does not address intracellular signal transduction"]},{"year":1993,"claim":"Identifying a complex between SFFV gp52 env and EpoR showed the receptor can be aberrantly engaged, but processing—not mere binding—drives pathogenic mitogenesis.","evidence":"Co-immunoprecipitation of gp52 with EpoR plus glycosylation mutants in mitogenicity and splenomegaly assays","pmids":["8437218"],"confidence":"Medium","gaps":["Mechanism of how processed gp52 activates EpoR not defined","Relevance to physiological EPO signaling limited"]},{"year":1997,"claim":"EPO was shown to activate Raf1/ERK through Shp2/Grb2 rather than Shc, distinguishing the EpoR MAPK arm from other cytokine receptors.","evidence":"EPO/IL-2/IL-15 stimulation of CTLL-EPO-R cells with Shc/Shp2 immunoprecipitation and Raf1/ERK2 kinase assays","pmids":["8978277"],"confidence":"Medium","gaps":["Receptor tyrosines responsible for Shp2/Grb2 recruitment not mapped here","Single-lab biochemistry"]},{"year":1998,"claim":"Replacing EpoR with the prolactin receptor in EpoR-/- progenitors established that EpoR provides a permissive, not instructive, signal for erythroid differentiation.","evidence":"Retroviral PrlR and PrlR/EpoR chimera transduction into EpoR-/- progenitors with prolactin/SCF differentiation assays","pmids":["9716574"],"confidence":"High","gaps":["Does not exclude EpoR-specific roles in non-erythroid tissues","Quantitative signaling differences not measured"]},{"year":1999,"claim":"A truncated EPOR isoform acting as a dominant negative linked aberrant receptor forms to ineffective erythropoiesis in disease.","evidence":"Stable EPOR-T transfection in UT-7/GM cells with apoptosis/hemoglobinization assays and RT-PCR in MDS patient samples","pmids":["10029161"],"confidence":"Medium","gaps":["Causal role of EPOR-T in MDS pathogenesis not established","Mechanism of dominant-negative interference not detailed"]},{"year":2001,"claim":"Genetic and developmental studies placed EpoR signaling as both essential for progenitor renewal via PI3K and sufficient to advance the developmental switch to definitive erythropoiesis.","evidence":"p53-/- erythroid progenitor lines with STAT5/PI3K inhibition, and a constitutively active EpoR-R129C knock-in mouse","pmids":["11439328","11520789"],"confidence":"High","gaps":["Downstream PI3K effectors for renewal not defined","How R129C accelerates the developmental switch mechanistically unclear"]},{"year":2002,"claim":"Mapping SOCS/CIS induction to STAT5 established the negative-feedback layer that limits EPOR proliferative signaling.","evidence":"STAT5/MAPK/PI3K inhibition, EpoR mutant lines activating signaling subsets, and inducible SOCS overexpression with reporter assays","pmids":["12396724"],"confidence":"Medium","gaps":["Receptor docking sites for individual SOCS proteins not all mapped","Relative in vivo contribution of each SOCS not addressed"]},{"year":2003,"claim":"Two studies refined the EPOR cytoplasmic survival code—SLAP as a STAT5-inhibiting negative regulator and a tyrosine-independent membrane-proximal STAT5 survival signal.","evidence":"SLAP-EpoR co-IP and overexpression in erythroblasts; tyrosine-null EPOR mutants with dominant-negative STAT5 in 32D cells","pmids":["12946994","14662339"],"confidence":"Medium","gaps":["How non-tyrosine sequences couple to STAT5 unresolved","SLAP interaction surface on EpoR not mapped"]},{"year":2006,"claim":"Genetic dissection established cell-autonomous requirements for EpoR, STAT5, and GR in erythroblast renewal and pinned terminal-differentiation survival on STAT5-driven Bcl-XL.","evidence":"Primary erythroblasts from EpoR-H, GRdim, and Stat5ab-/- mice with retroviral Bcl-XL rescue","pmids":["16407844"],"confidence":"High","gaps":["Integration of GR with EpoR/STAT5 signaling not molecularly defined","Targets beyond Bcl-XL not enumerated"]},{"year":2008,"claim":"EPOR signaling was extended beyond the marrow to hepatic iron regulation via C/EBPalpha-dependent hepcidin suppression, and to KIT co-signaling through Y343.","evidence":"Anti-EPOR blocking antibody and C/EBPalpha ChIP in hepatocytes; KIT/EpoR tyrosine-to-phenylalanine mutants in 32D proliferation assays","pmids":["18326822","18538998"],"confidence":"Medium","gaps":["Direct transcriptional mechanism linking EpoR to C/EBPalpha not resolved","In vivo relevance of KIT-EpoR Y343 cooperativity not tested genetically"]},{"year":2008,"claim":"Constitutively active STAT5 rescuing both Jak2-/- and EpoR-/- erythroid cells placed STAT5 as the critical effector node downstream of the receptor.","evidence":"Genetic rescue with cS5 in KO fetal liver cells, tamoxifen-inducible Stat5a-ER, and fetal liver transplantation","pmids":["18239084"],"confidence":"High","gaps":["Full STAT5 target program not defined here","Roles of parallel PI3K/ERK arms not separated"]},{"year":2009,"claim":"Defining clathrin-mediated EPOR endocytosis via JAK2, Y429/Y431/Y479, and p85 recruitment established the signal-termination machinery and its failure in PFCP.","evidence":"EpoR tyrosine mutagenesis, p85alpha/beta knockdown and dominant negatives, clathrin inhibition, and PFCP mutant analysis","pmids":["19336760"],"confidence":"High","gaps":["p85's PI3K-independent endocytic adaptor mechanism not fully detailed","Kinetics of receptor recycling vs. degradation not resolved"]},{"year":2012,"claim":"Multiple studies clarified EPOR trafficking, the molecular forms of the receptor, transcriptome targets, Spry1-mediated feedback, EpoR-independent JAK2V617F adhesion signaling, and EpoR control of red cell size.","evidence":"Domain-specific antibodies with N-glycanase/BFA; CFU-e transcriptome with Tnfr-sf13c validation; Mx1-Cre Spry1 deletion with LC-MS/MS PY53 discovery; EpoR knockdown in HEL cells; EpoR-/- and in vivo MCV measurements","pmids":["22253704","22808010","22508938","23160466","34921133"],"confidence":"High","gaps":["Mechanism coupling EpoR to MCV control not molecularly defined","Spry1 target (Jak2 vs ERK) directness not fully separated"]},{"year":2013,"claim":"Cbl-dependent p85 ubiquitination engaging epsin-1 completed the endocytic mechanism and explained PFCP Epo hypersensitivity via lost negative feedback.","evidence":"Cbl knockdown/dominant negatives, epsin-1 UIM mutants, co-localization, and rescue of p85-binding in PFCP receptors","pmids":["24113870"],"confidence":"High","gaps":["E3 ligase specificity for p85 vs receptor not fully resolved","In vivo contribution to polycythemia not genetically tested here"]},{"year":2014,"claim":"Chimeric-receptor analysis of PFCP mutants mechanistically linked C-terminal truncation to slower degradation, mature glycoforms, and extended signaling.","evidence":"EGFR-EPOR chimeras carrying PFCP deletions/nonsense/missense alleles with glycosylation, degradation, and signaling-duration readouts","pmids":["24533580"],"confidence":"Medium","gaps":["Chimeric system may not fully mimic native EPOR","Quantitative contribution of each mutation to disease severity unknown"]},{"year":2016,"claim":"Mapping CIS to phospho-Y401 connected a specific receptor docking site to STAT5/ERK control and tumor suppression in JAK2V617F cells.","evidence":"CIS-EpoR co-IP at Y401, CIS RNAi/overexpression with SH2 mutants, STAT5/ERK assays, and nude mouse tumor formation","pmids":["28038963"],"confidence":"Medium","gaps":["Direct vs indirect Y401-CIS binding not structurally confirmed","In vivo erythroid relevance of CIS-Y401 not tested"]},{"year":2020,"claim":"PTPN18 was identified as a JAK2-dependent EPO target phosphatase that sustains EPOR signaling and modulates receptor glycoforms and RHEX phosphorylation.","evidence":"Phospho-tyrosine PTM proteomics, PTPN18-Y389 mutagenesis, JAK2 inhibition, RHEX phospho-assays, and proliferation/survival readouts","pmids":["32027948"],"confidence":"Medium","gaps":["Direct PTPN18 substrates not all defined","In vivo erythroid role of PTPN18 untested"]},{"year":2021,"claim":"Tissue-specific genetics and reporters revealed EpoR function and expression beyond erythroid cells—in osteoprogenitors regulating bone, in EBI macrophages and diverse hematopoietic subsets, and a Rab26-dependent surface-trafficking requirement for macrophage M2 polarization.","evidence":"EpoR:Osx-cre cKO with histomorphometry and osteoclast co-culture; EpoR-tdTomato-Cre reporter with EPO injection; myeloid EPOR-deficient and Rab26-KO macrophages with eCIRP and polarization assays","pmids":["34518518","34098576","34925338"],"confidence":"High","gaps":["Whether non-erythroid EpoR uses identical JAK2/STAT5 wiring not fully established","Physiological ligand levels driving non-erythroid signaling unclear"]},{"year":2022,"claim":"Monocytic-lineage EPOR deletion showed EpoR signaling in osteoclast precursors mediates EPO-induced bone loss independently of erythropoiesis.","evidence":"LysMCre and Cx3cr1Cre EPOR cKO mice with EPO challenge, CD115+ preosteoclast flow cytometry, and microCT","pmids":["36233351"],"confidence":"Medium","gaps":["Downstream effectors in osteoclast precursors not mapped","Sex-specific effects not mechanistically explained"]},{"year":2023,"claim":"EpoR-driven JAK2 phosphorylation of p27Kip1 at Y88 was shown to convert p27 from CDK inhibitor to activator, providing a proliferative mechanism with an in vivo erythroid phenotype.","evidence":"p27-EpoR co-IP, Y88 phosphorylation with JAK2 inhibitor, p27Y88F knock-in mice, and CFU-E/CBC analysis","pmids":["37443738"],"confidence":"High","gaps":["Whether p27Y88 phosphorylation is direct by JAK2 not fully resolved","Contribution relative to STAT5-driven proliferation unquantified"]},{"year":2024,"claim":"An EPO-EpoR-RUNX1 axis in white adipose tissue was defined, where EPO stabilizes RUNX1 by lowering FBXW7 to suppress lipogenesis and control energy metabolism.","evidence":"Adipose-specific EpoR-KO mice with EPO treatment, RUNX1 stability and FBXW7 expression assays, and lipogenic gene profiling","pmids":["39284834"],"confidence":"High","gaps":["Signaling steps from EpoR to FBXW7 regulation not defined","Sex-specific (male) phenotype mechanism unexplained"]},{"year":null,"claim":"Whether non-erythroid EpoR functions (bone, adipose, macrophage) employ the same JAK2/STAT5/PI3K/ERK wiring and receptor tyrosines as erythroid signaling remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No tissue-by-tissue mapping of EpoR tyrosine usage","Endogenous ligand and dosage driving non-erythroid signaling unclear","No structural model of full-length receptor signaling complexes in the corpus"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[3,9,7]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[22,0]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[8,16,14]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,23,29]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[21,23]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[0,1,23]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,7,0]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[24,29,25]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[0,1,23]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[5,20]}],"complexes":[],"partners":["JAK2","STAT5A","PIK3R1","CBL","CISH","SLA","KIT","CDKN1B"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P19235","full_name":"Erythropoietin receptor","aliases":[],"length_aa":508,"mass_kda":55.1,"function":"Receptor for erythropoietin, which mediates erythropoietin-induced erythroblast proliferation and differentiation (PubMed:10388848, PubMed:2163695, PubMed:2163696, PubMed:8662939, PubMed:9774108). Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade (By similarity). In some cell types, can also activate STAT1 and STAT3 (PubMed:11756159). May also activate the LYN tyrosine kinase (By similarity) Acts as a dominant-negative receptor of EPOR-mediated signaling","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P19235/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/EPOR","classification":"Not Classified","n_dependent_lines":9,"n_total_lines":1208,"dependency_fraction":0.0074503311258278145},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/EPOR","total_profiled":1310},"omim":[{"mim_id":"620463","title":"ERYTHROID DIFFERENTIATION REGULATORY FACTOR 1; EDRF1","url":"https://www.omim.org/entry/620463"},{"mim_id":"617911","title":"DIAMOND-BLACKFAN ANEMIA-LIKE; DBAL","url":"https://www.omim.org/entry/617911"},{"mim_id":"616088","title":"REGULATOR OF HEMOGLOBINIZATION AND ERYTHROID CELL EXPANSION; RHEX","url":"https://www.omim.org/entry/616088"},{"mim_id":"612157","title":"SENTRIN-SPECIFIC PROTEASE FAMILY, MEMBER 1; SENP1","url":"https://www.omim.org/entry/612157"},{"mim_id":"607733","title":"SCRIBBLE PLANAR CELL POLARITY PROTEIN; SCRIB","url":"https://www.omim.org/entry/607733"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Nuclear speckles","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/EPOR"},"hgnc":{"alias_symbol":["EPO-R"],"prev_symbol":[]},"alphafold":{"accession":"P19235","domains":[{"cath_id":"2.60.40.10","chopping":"34-145","consensus_level":"high","plddt":91.609,"start":34,"end":145},{"cath_id":"2.60.40.10","chopping":"153-248","consensus_level":"high","plddt":88.8061,"start":153,"end":248},{"cath_id":"1.10.287","chopping":"249-281","consensus_level":"medium","plddt":85.5418,"start":249,"end":281}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P19235","model_url":"https://alphafold.ebi.ac.uk/files/AF-P19235-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P19235-F1-predicted_aligned_error_v6.png","plddt_mean":66.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=EPOR","jax_strain_url":"https://www.jax.org/strain/search?query=EPOR"},"sequence":{"accession":"P19235","fasta_url":"https://rest.uniprot.org/uniprotkb/P19235.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P19235/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P19235"}},"corpus_meta":[{"pmid":"18326822","id":"PMC_18326822","title":"Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18326822","citation_count":188,"is_preprint":false},{"pmid":"11439328","id":"PMC_11439328","title":"Leukemic transformation of normal murine erythroid progenitors: v- and c-ErbB act through signaling pathways activated by the EpoR and c-Kit in stress erythropoiesis.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11439328","citation_count":86,"is_preprint":false},{"pmid":"18239084","id":"PMC_18239084","title":"Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18239084","citation_count":85,"is_preprint":false},{"pmid":"20124514","id":"PMC_20124514","title":"Absence of functional EpoR expression in human tumor cell lines.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20124514","citation_count":83,"is_preprint":false},{"pmid":"23160466","id":"PMC_23160466","title":"JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23160466","citation_count":78,"is_preprint":false},{"pmid":"32265704","id":"PMC_32265704","title":"Suppression of NLRP3 Inflammasome by Erythropoietin via the EPOR/JAK2/STAT3 Pathway Contributes to Attenuation of Acute Lung Injury in Mice.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32265704","citation_count":72,"is_preprint":false},{"pmid":"29102603","id":"PMC_29102603","title":"Erythropoietin ameliorates early brain injury after subarachnoid haemorrhage by modulating microglia polarization via the EPOR/JAK2-STAT3 pathway.","date":"2017","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/29102603","citation_count":66,"is_preprint":false},{"pmid":"11520789","id":"PMC_11520789","title":"Erythropoietin (Epo) and EpoR expression and 2 waves of erythropoiesis.","date":"2001","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11520789","citation_count":57,"is_preprint":false},{"pmid":"19887071","id":"PMC_19887071","title":"Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells.","date":"2009","source":"Journal of immunological methods","url":"https://pubmed.ncbi.nlm.nih.gov/19887071","citation_count":57,"is_preprint":false},{"pmid":"9716574","id":"PMC_9716574","title":"The prolactin receptor rescues EpoR-/- erythroid progenitors and replaces EpoR in a synergistic interaction with c-kit.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9716574","citation_count":53,"is_preprint":false},{"pmid":"19336760","id":"PMC_19336760","title":"Ligand-induced EpoR internalization is mediated by JAK2 and p85 and is impaired by mutations responsible for primary familial and congenital polycythemia.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19336760","citation_count":47,"is_preprint":false},{"pmid":"34921133","id":"PMC_34921133","title":"EpoR stimulates rapid cycling and larger red cells during mouse and human erythropoiesis.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34921133","citation_count":46,"is_preprint":false},{"pmid":"16407844","id":"PMC_16407844","title":"Erythroid progenitor renewal versus differentiation: genetic evidence for cell autonomous, essential functions of EpoR, Stat5 and the GR.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16407844","citation_count":46,"is_preprint":false},{"pmid":"8978277","id":"PMC_8978277","title":"Erythropoietin activates Raf1 by an Shc-independent pathway in CTLL-EPO-R cells.","date":"1997","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/8978277","citation_count":43,"is_preprint":false},{"pmid":"12396724","id":"PMC_12396724","title":"Differential roles of SOCS family members in EpoR signal transduction.","date":"2002","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/12396724","citation_count":41,"is_preprint":false},{"pmid":"28488208","id":"PMC_28488208","title":"Erythropoietin Rescues Memory Impairment in a Rat Model of Chronic Cerebral Hypoperfusion via the EPO-R/JAK2/STAT5/PI3K/Akt/GSK-3β Pathway.","date":"2017","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28488208","citation_count":36,"is_preprint":false},{"pmid":"34098576","id":"PMC_34098576","title":"EpoR-tdTomato-Cre mice enable identification of EpoR expression in subsets of tissue macrophages and hematopoietic cells.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/34098576","citation_count":35,"is_preprint":false},{"pmid":"1962754","id":"PMC_1962754","title":"Assignment of the erythropoietin receptor (EPOR) gene to mouse chromosome 9 and human chromosome 19.","date":"1990","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1962754","citation_count":35,"is_preprint":false},{"pmid":"28064106","id":"PMC_28064106","title":"Neuroprotective effects of erythropoietin against sevoflurane-induced neuronal apoptosis in primary rat cortical neurons involving the EPOR-Erk1/2-Nrf2/Bach1 signal pathway.","date":"2017","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/28064106","citation_count":35,"is_preprint":false},{"pmid":"24113870","id":"PMC_24113870","title":"Cbl ubiquitination of p85 is essential for Epo-induced EpoR endocytosis.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/24113870","citation_count":32,"is_preprint":false},{"pmid":"7601257","id":"PMC_7601257","title":"Lineage-restricted recruitment of immature hematopoietic progenitor cells in response to Epo after normal hematopoietic cell transfection with EpoR.","date":"1995","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/7601257","citation_count":32,"is_preprint":false},{"pmid":"30361931","id":"PMC_30361931","title":"Venlafaxine Mitigates Depressive-Like Behavior in Ovariectomized Rats by Activating the EPO/EPOR/JAK2 Signaling Pathway and Increasing the Serum Estradiol Level.","date":"2019","source":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/30361931","citation_count":31,"is_preprint":false},{"pmid":"27543111","id":"PMC_27543111","title":"Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EpoR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts.","date":"2016","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27543111","citation_count":29,"is_preprint":false},{"pmid":"18495932","id":"PMC_18495932","title":"Synergistic upregulation of erythropoietin receptor (EPO-R) expression by sense and antisense EPO-R transcripts in the canine lung.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18495932","citation_count":28,"is_preprint":false},{"pmid":"29051279","id":"PMC_29051279","title":"Expansion of EPOR-negative macrophages besides erythroblasts by elevated EPOR signaling in erythrocytosis mouse models.","date":"2017","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/29051279","citation_count":27,"is_preprint":false},{"pmid":"27470403","id":"PMC_27470403","title":"Erythropoietin attenuates renal and pulmonary injury in polymicrobial induced-sepsis through EPO-R, VEGF and VEGF-R2 modulation.","date":"2016","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/27470403","citation_count":27,"is_preprint":false},{"pmid":"34518518","id":"PMC_34518518","title":"Epo/EpoR signaling in osteoprogenitor cells is essential for bone homeostasis and Epo-induced bone loss.","date":"2021","source":"Bone research","url":"https://pubmed.ncbi.nlm.nih.gov/34518518","citation_count":26,"is_preprint":false},{"pmid":"28418910","id":"PMC_28418910","title":"Erythropoietin drives breast cancer progression by activation of its receptor EPOR.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28418910","citation_count":26,"is_preprint":false},{"pmid":"24761846","id":"PMC_24761846","title":"Ginsenoside Rg1 induces apoptosis through inhibition of the EpoR-mediated JAK2/STAT5 signalling pathway in the TF-1/ Epo human leukemia cell line.","date":"2014","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/24761846","citation_count":26,"is_preprint":false},{"pmid":"29181060","id":"PMC_29181060","title":"Expression of multidrug resistance protein P-glycoprotein in correlation with markers of hypoxia (HIF-1α, EPO, EPO-R) in invasive breast cancer with metastasis to lymph nodes.","date":"2016","source":"Archives of medical science : AMS","url":"https://pubmed.ncbi.nlm.nih.gov/29181060","citation_count":26,"is_preprint":false},{"pmid":"20189893","id":"PMC_20189893","title":"Testosterone membrane-initiated action in breast cancer cells: Interaction with the androgen signaling pathway and EPOR.","date":"2010","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20189893","citation_count":25,"is_preprint":false},{"pmid":"34925338","id":"PMC_34925338","title":"Extracellular CIRP-Impaired Rab26 Restrains EPOR-Mediated Macrophage Polarization in Acute Lung Injury.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34925338","citation_count":23,"is_preprint":false},{"pmid":"8437218","id":"PMC_8437218","title":"Erythropoietin receptor (EpoR)-dependent mitogenicity of spleen focus-forming virus correlates with viral pathogenicity and processing of env protein but not with formation of gp52-EpoR complexes in the endoplasmic reticulum.","date":"1993","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/8437218","citation_count":23,"is_preprint":false},{"pmid":"21339183","id":"PMC_21339183","title":"Different expression patterns of Ngb and EPOR in the cerebral cortex and hippocampus revealed distinctive therapeutic effects of intranasal delivery of Neuro-EPO for ischemic insults to the gerbil brain.","date":"2011","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/21339183","citation_count":23,"is_preprint":false},{"pmid":"10029161","id":"PMC_10029161","title":"Dominant negative effect of a truncated erythropoietin receptor (EPOR-T) on erythropoietin-induced erythroid differentiation: possible involvement of EPOR-T in ineffective erythropoiesis of myelodysplastic syndrome.","date":"1999","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/10029161","citation_count":23,"is_preprint":false},{"pmid":"35839275","id":"PMC_35839275","title":"Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia.","date":"2022","source":"Blood cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35839275","citation_count":22,"is_preprint":false},{"pmid":"7686789","id":"PMC_7686789","title":"Anti-erythropoietin receptor (EPO-R) monoclonal antibodies inhibit erythropoietin binding and neutralize bioactivity.","date":"1993","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7686789","citation_count":22,"is_preprint":false},{"pmid":"31055001","id":"PMC_31055001","title":"Aqueous extract from You-Gui-Yin ameliorates cognitive impairment of chronic renal failure mice through targeting hippocampal CaMKIIα/CREB/BDNF and EPO/EPOR pathways.","date":"2019","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31055001","citation_count":22,"is_preprint":false},{"pmid":"23615965","id":"PMC_23615965","title":"Erythropoietin receptor (EpoR) agonism is used to treat a wide range of disease.","date":"2013","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/23615965","citation_count":21,"is_preprint":false},{"pmid":"12946994","id":"PMC_12946994","title":"Up-regulation of SLAP in FLI-1-transformed erythroblasts interferes with EpoR signaling.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12946994","citation_count":19,"is_preprint":false},{"pmid":"9332307","id":"PMC_9332307","title":"An erythroid and megakaryocytic common precursor cell line (B1647) expressing both c-mpl and erythropoietin receptor (Epo-R) proliferates and modifies globin chain synthesis in response to megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo).","date":"1997","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/9332307","citation_count":19,"is_preprint":false},{"pmid":"11911958","id":"PMC_11911958","title":"Quantitation of the mRNA levels of Epo and EpoR in various tissues in the ovine fetus.","date":"2002","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11911958","citation_count":18,"is_preprint":false},{"pmid":"17493011","id":"PMC_17493011","title":"De novo erythropoietin receptor (EPO-R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survival.","date":"2007","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/17493011","citation_count":18,"is_preprint":false},{"pmid":"22253704","id":"PMC_22253704","title":"Dynamic ligand modulation of EPO receptor pools, and dysregulation by polycythemia-associated EPOR alleles.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22253704","citation_count":17,"is_preprint":false},{"pmid":"7795240","id":"PMC_7795240","title":"Constitutive expression of GATA-1, EPOR, alpha-globin, and gamma-globin genes in myeloid clonogenic cells from juvenile chronic myelocytic leukemia.","date":"1995","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7795240","citation_count":17,"is_preprint":false},{"pmid":"17597020","id":"PMC_17597020","title":"STAT3, HIF-1alpha, EPO and EPOR - signaling proteins in human primary ductal breast cancers.","date":"2007","source":"Folia histochemica et cytobiologica","url":"https://pubmed.ncbi.nlm.nih.gov/17597020","citation_count":16,"is_preprint":false},{"pmid":"30583863","id":"PMC_30583863","title":"Erythropoietin and long-acting erythropoiesis stimulating agent ameliorate non-alcoholic fatty liver disease by increasing lipolysis and decreasing lipogenesis via EPOR/STAT pathway.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30583863","citation_count":16,"is_preprint":false},{"pmid":"24489649","id":"PMC_24489649","title":"Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24489649","citation_count":16,"is_preprint":false},{"pmid":"22808010","id":"PMC_22808010","title":"Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22808010","citation_count":16,"is_preprint":false},{"pmid":"25807104","id":"PMC_25807104","title":"Functional EpoR pathway utilization is not detected in primary tumor cells isolated from human breast, non-small cell lung, colorectal, and ovarian tumor tissues.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25807104","citation_count":15,"is_preprint":false},{"pmid":"27629849","id":"PMC_27629849","title":"Expression of Hypoxia-Inducible Factor 1α in Invasive Breast Cancer with Metastasis to Lymph Nodes: Correlation with Steroid Receptors, HER2 and EPO-R.","date":"2016","source":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/27629849","citation_count":15,"is_preprint":false},{"pmid":"24533580","id":"PMC_24533580","title":"Polycythaemia-inducing mutations in the erythropoietin receptor (EPOR): mechanism and function as elucidated by epidermal growth factor receptor-EPOR chimeras.","date":"2014","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/24533580","citation_count":14,"is_preprint":false},{"pmid":"30038572","id":"PMC_30038572","title":"The Effects of Curcumae Longae Radix, Curcuma phaeocaulis Radix and Their Processed Products on Epo/EpoR Pathway and CD62p.","date":"2018","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30038572","citation_count":14,"is_preprint":false},{"pmid":"24497137","id":"PMC_24497137","title":"The relationships between hypoxia-dependent markers: HIF-1alpha, EPO and EPOR in colorectal cancer.","date":"2013","source":"Folia histochemica et cytobiologica","url":"https://pubmed.ncbi.nlm.nih.gov/24497137","citation_count":13,"is_preprint":false},{"pmid":"20164027","id":"PMC_20164027","title":"STAT3 and hypoxia induced proteins--HIF-1alpha, EPO and EPOR in relation with Bax and Bcl-xL in nodal metastases of ductal breast cancers.","date":"2009","source":"Folia histochemica et cytobiologica","url":"https://pubmed.ncbi.nlm.nih.gov/20164027","citation_count":13,"is_preprint":false},{"pmid":"27468719","id":"PMC_27468719","title":"Tumor biology of non-metastatic stages of clear cell renal cell carcinoma; overexpression of stearoyl desaturase-1, EPO/EPO-R system and hypoxia-related proteins.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27468719","citation_count":13,"is_preprint":false},{"pmid":"39284834","id":"PMC_39284834","title":"Erythropoietin regulates energy metabolism through EPO-EpoR-RUNX1 axis.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39284834","citation_count":12,"is_preprint":false},{"pmid":"31082798","id":"PMC_31082798","title":"EPO-R+ myelodysplastic cells with ring sideroblasts produce high erythroferrone levels to reduce hepcidin expression in hepatic cells.","date":"2019","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/31082798","citation_count":12,"is_preprint":false},{"pmid":"33811103","id":"PMC_33811103","title":"Erythropoietin Protects against Diffuse Alveolar Hemorrhage in Mice by Regulating Macrophage Polarization through the EPOR/JAK2/STAT3 Axis.","date":"2021","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/33811103","citation_count":12,"is_preprint":false},{"pmid":"25219375","id":"PMC_25219375","title":"Activity increase in EpoR and Epo expression by intranasal recombinant human erythropoietin (rhEpo) administration in ischemic hippocampi of adult rats.","date":"2014","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/25219375","citation_count":12,"is_preprint":false},{"pmid":"19735711","id":"PMC_19735711","title":"Total saponins of Panax ginseng (TSPG) promote erythroid differentiation of human CD34+ cells via EpoR-mediated JAK2/STAT5 signaling pathway.","date":"2009","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19735711","citation_count":12,"is_preprint":false},{"pmid":"24030742","id":"PMC_24030742","title":"B acute lymphoblastic leukemia with t(14;19)(q32;p13.1) involving IGH/EPOR: a clinically aggressive subset of disease.","date":"2013","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/24030742","citation_count":12,"is_preprint":false},{"pmid":"36233351","id":"PMC_36233351","title":"Erythropoietin Receptor (EPOR) Signaling in the Osteoclast Lineage Contributes to EPO-Induced Bone Loss in Mice.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36233351","citation_count":11,"is_preprint":false},{"pmid":"37663284","id":"PMC_37663284","title":"RNA N6-methyladenosine reader IGF2BP3 promotes acute myeloid leukemia progression by controlling stabilization of EPOR mRNA.","date":"2023","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/37663284","citation_count":11,"is_preprint":false},{"pmid":"22508938","id":"PMC_22508938","title":"Spry1 as a novel regulator of erythropoiesis, EPO/EPOR target, and suppressor of JAK2.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22508938","citation_count":11,"is_preprint":false},{"pmid":"32027948","id":"PMC_32027948","title":"Phospho-PTM proteomic discovery of novel EPO- modulated kinases and phosphatases, including PTPN18 as a positive regulator of EPOR/JAK2 Signaling.","date":"2020","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/32027948","citation_count":11,"is_preprint":false},{"pmid":"20336349","id":"PMC_20336349","title":"Immunohistochemical detection of phosphorylated JAK-2 and STAT-5 proteins and correlation with erythropoietin receptor (EpoR) expression status in human brain tumors.","date":"2010","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20336349","citation_count":11,"is_preprint":false},{"pmid":"26122516","id":"PMC_26122516","title":"EPOR-Based Purification and Analysis of Erythropoietin Mimetic Peptides from Human Urine by Cys-Specific Cleavage and LC/MS/MS.","date":"2015","source":"Journal of the American Society for Mass Spectrometry","url":"https://pubmed.ncbi.nlm.nih.gov/26122516","citation_count":11,"is_preprint":false},{"pmid":"30271932","id":"PMC_30271932","title":"A truncating mutation in EPOR leads to hypo-responsiveness to erythropoietin with normal haemoglobin.","date":"2018","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/30271932","citation_count":11,"is_preprint":false},{"pmid":"29223734","id":"PMC_29223734","title":"Activation of the EPOR-β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes.","date":"2017","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/29223734","citation_count":11,"is_preprint":false},{"pmid":"28038963","id":"PMC_28038963","title":"Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR.","date":"2016","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/28038963","citation_count":10,"is_preprint":false},{"pmid":"32739800","id":"PMC_32739800","title":"Novel mutations in the EPO-R, VHL and EPAS1 genes in the Congenital Erythrocytosis patients.","date":"2020","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/32739800","citation_count":10,"is_preprint":false},{"pmid":"32908942","id":"PMC_32908942","title":"Identification and Functional Analysis of EPOR+ Tumor-Associated Macrophages in Human Osteosarcoma Lung Metastasis.","date":"2020","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/32908942","citation_count":10,"is_preprint":false},{"pmid":"14662339","id":"PMC_14662339","title":"Hematopoietic cell survival signals are elicited through non-tyrosine-containing sequences in the membrane-proximal region of the erythropoietin receptor (EPOR) by a Stat5-dependent pathway.","date":"2003","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/14662339","citation_count":10,"is_preprint":false},{"pmid":"18538998","id":"PMC_18538998","title":"KIT associated intracellular tyrosines play an essential role in EpoR co-signaling.","date":"2008","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/18538998","citation_count":9,"is_preprint":false},{"pmid":"35355248","id":"PMC_35355248","title":"An inherited gain-of-function risk allele in EPOR predisposes to familial JAK2V617F myeloproliferative neoplasms.","date":"2022","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/35355248","citation_count":8,"is_preprint":false},{"pmid":"29127105","id":"PMC_29127105","title":"EPOR2/βcR2-independendent effects of low-dose epoetin-α in porcine liver transplantation.","date":"2017","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/29127105","citation_count":7,"is_preprint":false},{"pmid":"22844537","id":"PMC_22844537","title":"The expression of EPOR in renal cortex during postnatal development.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22844537","citation_count":7,"is_preprint":false},{"pmid":"29623657","id":"PMC_29623657","title":"A case of primary familial congenital polycythemia with a novel EPOR mutation: possible spontaneous remission/alleviation by menstrual bleeding.","date":"2018","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/29623657","citation_count":7,"is_preprint":false},{"pmid":"22077413","id":"PMC_22077413","title":"Mast cells in canine mammary gland tumour: number, distribution and EPOR positivity.","date":"2011","source":"Veterinary and comparative oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22077413","citation_count":6,"is_preprint":false},{"pmid":"23577103","id":"PMC_23577103","title":"Changes in the Expression of Transcription Factors Involved in Modulating the Expression of EPO-R in Activated Human CD4-Positive Lymphocytes.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23577103","citation_count":6,"is_preprint":false},{"pmid":"11042699","id":"PMC_11042699","title":"SPI-1 transforming properties depend upon specifically activated forms of the EPOR.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11042699","citation_count":6,"is_preprint":false},{"pmid":"37443738","id":"PMC_37443738","title":"EpoR Activation Stimulates Erythroid Precursor Proliferation by Inducing Phosphorylation of Tyrosine-88 of the CDK-Inhibitor p27Kip1.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/37443738","citation_count":5,"is_preprint":false},{"pmid":"37204242","id":"PMC_37204242","title":"EPOR activation attenuates colitis via enhancing LC3B-dependent apoptotic cell clearance.","date":"2023","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37204242","citation_count":5,"is_preprint":false},{"pmid":"39894850","id":"PMC_39894850","title":"Overview of preclinical and phase II clinical studies on Pegmolesatide's long-term erythropoiesis stimulating effect via EPOR-mediated signal transduction.","date":"2025","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39894850","citation_count":5,"is_preprint":false},{"pmid":"19846965","id":"PMC_19846965","title":"Relationships of P53 and Bak with EPO and EPOR in human colorectal cancer.","date":"2009","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19846965","citation_count":5,"is_preprint":false},{"pmid":"19002875","id":"PMC_19002875","title":"Growth control of hybridoma cells with an artificially induced EpoR-gp130 heterodimer.","date":"2006","source":"Cytotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/19002875","citation_count":5,"is_preprint":false},{"pmid":"28256220","id":"PMC_28256220","title":"Do All X-ray Structures of Protein-Ligand Complexes Represent Functional States? EPOR, a Case Study.","date":"2017","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/28256220","citation_count":5,"is_preprint":false},{"pmid":"26897933","id":"PMC_26897933","title":"Mystery Story about Erythropoietin (Epo) and Erythropoietin Receptor (EpoR) are Disguised?","date":"2015","source":"Hepato-gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/26897933","citation_count":4,"is_preprint":false},{"pmid":"36292571","id":"PMC_36292571","title":"Identification of Two Novel EPOR Gene Variants in Primary Familial Polycythemia: Case Report and Literature Review.","date":"2022","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/36292571","citation_count":4,"is_preprint":false},{"pmid":"38796216","id":"PMC_38796216","title":"Shengmaisan combined with Liuwei Dihuang Decoction alleviates chronic intermittent hypoxia-induced cognitive impairment by activating the EPO/EPOR/JAK2 signaling pathway.","date":"2024","source":"Chinese journal of natural medicines","url":"https://pubmed.ncbi.nlm.nih.gov/38796216","citation_count":4,"is_preprint":false},{"pmid":"38907076","id":"PMC_38907076","title":"Microglial EPOR Contribute to Sevoflurane-induced Developmental Fine Motor Deficits Through Synaptic Pruning in Mice.","date":"2024","source":"Neuroscience bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/38907076","citation_count":4,"is_preprint":false},{"pmid":"17213037","id":"PMC_17213037","title":"Immunohistochemical expression of p53, Bcl-2, COX-2, C-erb-B2, EPO-R, beta-catenin, and E-cadherin in non tumoral gastric mucous membrane.","date":"2006","source":"European journal of histochemistry : EJH","url":"https://pubmed.ncbi.nlm.nih.gov/17213037","citation_count":4,"is_preprint":false},{"pmid":"35274823","id":"PMC_35274823","title":"Erythroid-specific inactivation of Slc12a6/Kcc3 by EpoR promoter-driven Cre expression reduces K-Cl cotransport activity in mouse erythrocytes.","date":"2022","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/35274823","citation_count":3,"is_preprint":false},{"pmid":"22338178","id":"PMC_22338178","title":"[EPOR and TPOR expressions on CD34+ CD59- and CD34+ CD59+ bone marrow cells from patients with paroxysmal nocturnal hemoglobinuria].","date":"2011","source":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","url":"https://pubmed.ncbi.nlm.nih.gov/22338178","citation_count":3,"is_preprint":false},{"pmid":"27544511","id":"PMC_27544511","title":"Development of acute lymphoblastic leukemia with IgH-EPOR in a patient with secondary erythrocytosis.","date":"2016","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/27544511","citation_count":3,"is_preprint":false},{"pmid":"37794768","id":"PMC_37794768","title":"Learning induces EPO/EPOr expression in memory relevant brain areas, whereas exogenously applied EPO promotes remote memory consolidation.","date":"2023","source":"Synapse (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/37794768","citation_count":2,"is_preprint":false},{"pmid":"35395428","id":"PMC_35395428","title":"Novel mutations in EPO-R and oxygen-dependent degradation (ODD) domain of EPAS1 genes-a causative reason for Congenital Erythrocytosis.","date":"2022","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35395428","citation_count":2,"is_preprint":false},{"pmid":"38263262","id":"PMC_38263262","title":"Angiogenic responses are enhanced by recombinant human erythropoietin in a model of periventricular white matter damage of neonatal rats through EPOR-ERK1 signaling.","date":"2024","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/38263262","citation_count":2,"is_preprint":false},{"pmid":"19002606","id":"PMC_19002606","title":"EPO-R expression patterns in resected gastric adenocarcinoma followed by adjuvant chemoradiation treatment.","date":"2008","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/19002606","citation_count":2,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":55370,"output_tokens":8552,"usd":0.147195,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18397,"output_tokens":6479,"usd":0.12698,"stage2_stop_reason":"end_turn"},"total_usd":0.274175,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2009,\n      \"finding\": \"Epo-induced endocytosis of EpoR occurs via clathrin-mediated endocytosis. Both JAK2 kinase activity and EpoR cytoplasmic tyrosines (Y429, Y431, Y479) are required for ligand-dependent EpoR internalization. Phosphorylated Y429, Y431, and Y479 bind the p85 subunit of PI3K upon Epo stimulation, and p85α/β recruit endocytic machinery in a PI3K activity-independent manner. Truncated EpoRs from PFCP patients lacking these tyrosines fail to bind p85 or internalize upon stimulation.\",\n      \"method\": \"Mutagenesis of EpoR cytoplasmic tyrosines, knockdown of p85α/p85β with dominant-negative constructs, clathrin inhibition assays, analysis of PFCP patient receptor mutants\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro mutagenesis combined with multiple orthogonal methods (knockdown, dominant negatives, patient mutant analysis) in a single rigorous study\",\n      \"pmids\": [\"19336760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Epo induces Cbl-dependent ubiquitination of the p85 regulatory subunit of PI3K, which is bound to phosphotyrosines on EpoR. Ubiquitinated p85 interacts with endocytic protein epsin-1, driving EpoR endocytosis. Knockdown of Cbl or expression of epsin-1 mutants lacking ubiquitin-interacting motifs impairs EpoR internalization. PFCP-mimicking EpoR mutants cannot bind p85, co-localize with epsin-1, or internalize, causing Epo hypersensitivity. Restoring p85 binding to PFCP receptors rescues epsin-1 co-localization and EpoR internalization.\",\n      \"method\": \"Cbl knockdown, dominant-negative Cbl expression, epsin-1 UIM mutants, co-localization assays, primary erythroid progenitor knockdown, rescue experiments with restored p85-binding EpoR\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple orthogonal methods (knockdown, dominant negatives, mutagenesis, rescue) in a single rigorous study establishing a novel pathway\",\n      \"pmids\": [\"24113870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"EPO regulates hepcidin expression in a dose-dependent manner in hepatocytes through EPOR signaling. This is mediated through the transcription factor C/EBPα: EPO treatment decreases C/EBPα binding to the hepcidin promoter, as shown by chromatin immunoprecipitation. Pre-treatment with an EPOR-blocking antibody restores hepcidin mRNA levels, confirming EPOR dependence.\",\n      \"method\": \"Anti-EPOR blocking antibody, chromatin immunoprecipitation (ChIP) for C/EBPα at the hepcidin promoter, RT-PCR/Western blot for C/EBPα, freshly isolated mouse hepatocytes and HepG2 cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal functional blocking antibody plus ChIP, single lab with two orthogonal methods\",\n      \"pmids\": [\"18326822\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Constitutively activated Stat5a (cS5) is sufficient to rescue erythroid proliferation in both Jak2−/− and EpoR−/− cells in an Epo-independent manner, and tamoxifen-induced DNA binding of a Stat5a-ER fusion construct enables erythropoiesis in the absence of Epo. This places activated Stat5 as a critical downstream effector of Jak2 in erythropoiesis, functionally downstream of EpoR.\",\n      \"method\": \"Genetic rescue with constitutively active Stat5a mutant in Jak2−/− and EpoR−/− fetal liver cells, tamoxifen-inducible Stat5a-ER construct, fetal liver transplantation into irradiated mice\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — epistasis by genetic rescue with multiple complementary approaches (cS5 in KO cells, inducible system, transplantation), rigorous in vivo validation\",\n      \"pmids\": [\"18239084\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Stat5 and PI3K signaling pathways are utilized by both EpoR/c-Kit and v/c-ErbB in erythroid progenitor expansion. v-ErbB-transformed cells and normal progenitors depend on PI3K signaling for renewal, establishing that EpoR-driven PI3K signaling is essential for erythroid progenitor renewal.\",\n      \"method\": \"Immortalized erythroid progenitor lines from p53−/− fetal livers, ErbB inhibition, inhibition of Stat5 and PI3K, comparison with EpoR/c-Kit–driven expansion\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition plus genetic cell lines, single lab\",\n      \"pmids\": [\"11439328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"EpoR expression and activation regulate the timing of the definitive wave of erythropoiesis. A constitutively active form of EpoR (R129C EpoR) knocked into mice leads to earlier onset of definitive erythropoiesis in the yolk sac, demonstrating that EpoR signaling activation is sufficient to advance the developmental switch between primitive and definitive erythropoiesis.\",\n      \"method\": \"Knock-in mouse model with constitutively active EpoR-R129C, spatial/temporal analysis of Epo and EpoR gene expression during embryogenesis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic knock-in with defined developmental phenotypic readout, establishing EpoR as a direct regulator of erythroid wave timing\",\n      \"pmids\": [\"11520789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The prolactin receptor (PrlR) can fully replace EpoR in supporting terminal differentiation of EpoR−/− erythroid progenitors, demonstrating that EpoR has no instructive or unique signaling role in red blood cell differentiation beyond generic cytokine receptor signaling. Additionally, the synergistic interaction between EpoR and c-Kit is fully reproduced by PrlR and c-Kit, showing no requirement for an EpoR-unique signal in this synergism.\",\n      \"method\": \"Retroviral transduction of PrlR and PrlR/EpoR chimera into EpoR−/− progenitors, in vitro differentiation assays with prolactin and stem cell factor\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic rescue experiment with EpoR−/− cells using chimeric receptors, multiple readouts, directly testing instructive vs. permissive signaling\",\n      \"pmids\": [\"9716574\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"EPO activates the Raf1/MEK/MAP kinase pathway independently of Shc phosphorylation in CTLL-EPO-R cells. While IL-2 and IL-15 stimulate Shc tyrosine phosphorylation, EPO does not activate Shc but instead activates Raf1 and ERK2 through Shp2/Grb2/receptor complexes, establishing an Shc-independent Raf1 activation pathway downstream of EpoR.\",\n      \"method\": \"Stimulation of CTLL-EPO-R cells with EPO/IL-2/IL-15, immunoprecipitation of Shc and Shp2, Raf1 kinase assay, ERK2 kinase assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro kinase assays and co-immunoprecipitation, single lab with two orthogonal methods\",\n      \"pmids\": [\"8978277\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"SOCS1, SOCS2, SOCS3, and CIS induction by EPO depends on Stat5 but not on MAPK or PI3K. SOCS1, SOCS3, and CIS overexpression negatively regulate EPO-mediated cell proliferation and Stat5 phosphorylation; SOCS2 is less effective; SOCS4 is ineffective. These results establish differential roles of SOCS family members downstream of EPOR signaling.\",\n      \"method\": \"Inhibition of specific signaling molecules (Stat5, MAPK, PI3K), EpoR mutant cell lines activating only subsets of signaling cascades, stable inducible SOCS overexpression cell lines, luciferase reporter assays\",\n      \"journal\": \"Journal of interferon & cytokine research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two independent experimental approaches (signaling inhibitors plus EpoR mutant lines) in a single lab\",\n      \"pmids\": [\"12396724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Functional EpoR, Stat5, and glucocorticoid receptor (GR) are each cell-autonomously required for erythroblast renewal in vitro. Cells from EpoR-H mutant mice show enhanced differentiation instead of renewal. Additionally, Stat5ab is required for Epo-induced terminal differentiation: Stat5ab−/− differentiating erythroblasts undergo apoptosis due to absent Bcl-XL induction, a defect fully rescued by exogenous Bcl-XL.\",\n      \"method\": \"Primary erythroblast cultures from EpoRH, GRdim/dim, and Stat5ab−/− mice; retroviral Bcl-XL rescue; proliferation and differentiation assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic mutant mouse lines with rescue experiment, establishing cell-autonomous pathway requirements with defined molecular mechanism\",\n      \"pmids\": [\"16407844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"SLAP (Src-like adaptor protein) forms a specific complex with EpoR in FLI-1-transformed erythroblasts. Constitutive SLAP expression severely impairs Epo-induced erythroid differentiation by inhibiting STAT5 activation and Bcl-X gene upregulation downstream of EpoR, establishing SLAP as a negative regulator of EpoR signaling.\",\n      \"method\": \"Co-immunoprecipitation of SLAP with EpoR, stable SLAP expression in primary erythroblasts, STAT5 phosphorylation assays, hemoglobinization assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — co-IP establishing complex plus functional overexpression with specific signaling readouts, single lab\",\n      \"pmids\": [\"12946994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"EpoR signaling increases red cell size (MCV) while also increasing the number and speed of erythroblast cell cycles. EpoR-regulation of cell size is independent of iron-based size regulation. High EPO increases MCV in wild-type mice and human volunteers, and this effect outlasts EPO treatment duration.\",\n      \"method\": \"EpoR−/− erythroblasts with survival rescue signaling, comparison of cycling parameters, EPO injection in wild-type mice and human volunteers, MCV measurements\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — EpoR−/− genetic system plus in vivo mouse and human data, multiple orthogonal readouts\",\n      \"pmids\": [\"34921133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"JAK2V617F activates Lu/BCAM-mediated red cell adhesion through an EpoR-independent Rap1/Akt signaling pathway. Knockdown of EpoR in HEL cells does not alter Akt activity or cell adhesion to laminin, establishing that this JAK2V617F-driven pathway is distinct from EpoR.\",\n      \"method\": \"EpoR knockdown in HEL cells, dominant-negative Rap1S17N expression, Rap1 inhibitor GGTI-298, phospho-Akt measurement, laminin adhesion assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown plus pharmacological inhibition and dominant-negative approaches, single lab\",\n      \"pmids\": [\"23160466\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"EPOR-regulated transcriptome analysis in primary CFU-e progenitors identified 160 EPO/EPOR target transcripts. SOCS2, Socs3, Spred1, Spred2, and Eaf1 serve as negative-feedback components. The atypical TNF-receptor Tnfr-sf13c is upregulated >5-fold by EPO via EPOR/Jak2/Stat5 and promotes proerythroblast survival and erythroblast formation.\",\n      \"method\": \"Global transcriptome analysis of primary bone marrow CFU-e progenitors, Tnfr-sf13c ligation survival assays, identification of EPOR/Jak2/Stat5 response genes\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptome screen plus functional validation of Tnfr-sf13c in survival assays, single lab\",\n      \"pmids\": [\"22808010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Spry1 is selectively expressed in CFU-e to erythroblast stages and is phosphorylated at its conserved PY53 motif by EpoR signaling upon EPO stimulation (discovered by LC-MS/MS). Conditional Spry1 deletion leads to hyperactivation of Erk1/2 and Jak2 in erythroid progenitors, identifying Spry1 as a negative feedback regulator and candidate suppressor of Jak2 downstream of EpoR.\",\n      \"method\": \"Mx1-Cre conditional Spry1 deletion, LC-MS/MS phosphoproteomic discovery of Spry1-PY53, signaling analysis in Spry1-null progenitors, anemia challenge models\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — MS-based phosphosite discovery plus in vivo genetic deletion with defined signaling phenotype, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"22508938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PTPN18, identified by phospho-tyrosine PTM proteomics as a novel EPO target (phosphorylated at Y389 in a JAK2-dependent manner), promotes EPO-dependent hematopoietic cell proliferation and survival. PTPN18 sustains EPO-induced activation of ERK1/2, AKT, STAT5, and JAK2. It also increases high-molecular-weight EPOR forms while inhibiting EPO-induced phosphorylation of the EPOR-associated adaptor RHEX at Y141. Each effect depends on PTPN18-Y389.\",\n      \"method\": \"Phospho-tyrosine PTM proteomics, ectopic PTPN18 expression, JAK2 inhibitor treatment, RHEX phosphorylation assays, cell proliferation/survival assays, EPOR molecular weight analysis\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — proteomics discovery plus mutagenesis and functional assays, single lab\",\n      \"pmids\": [\"32027948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CIS interacts with phosphorylated EpoR at Y401, which is critical for STAT5 and ERK activation. The SH2 domain and tyrosine phosphorylation of CIS at Y253 are required for its tumor-suppressive anti-proliferative effects in JAK2V617F-transformed cells. CIS knockdown enhances STAT5 and ERK activation in JAK2V617F cells; CIS overexpression suppresses these signals and inhibits tumor formation.\",\n      \"method\": \"CIS-EpoR co-immunoprecipitation at Y401, CIS RNA interference, CIS overexpression with SH2 domain mutants, STAT5/ERK phosphorylation assays, nude mouse tumor formation assay\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP at specific phosphotyrosine plus mutagenesis and functional rescue assays, single lab\",\n      \"pmids\": [\"28038963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Non-tyrosine-containing sequences in the membrane-proximal region of EPOR elicit an important Stat5-dependent cell survival signal in 32D cells, independently of EpoR cytoplasmic tyrosines. This survival signal is serum-independent, revealing a previously unrecognized Stat5-dependent survival pathway in the EPOR cytoplasmic region.\",\n      \"method\": \"Stable transfection of 32D cells with wild-type and tyrosine-null EPOR mutants, dominant-inhibitory Stat5 isoform expression, EPO-dependent survival and proliferation assays\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis combined with dominant-negative Stat5, single lab, multiple receptor mutants tested\",\n      \"pmids\": [\"14662339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"KIT-associated intracellular tyrosines, particularly those binding Src kinases, are required for EpoR co-signaling. EpoR-Y343 is the single most important EpoR tyrosine for proliferation cooperativity with KIT, inducing Stat5, PI3K/Akt, and Erk1/2 activation. Restoration of the PLC-γ binding site in KIT antagonizes co-signaling with EpoR, while the Src binding sites are sufficient for restoring KIT–EpoR co-signaling.\",\n      \"method\": \"Co-expression of KIT and EpoR tyrosine-to-phenylalanine mutants in 32D cells, proliferation assays, STAT5/Akt/ERK phosphorylation analysis\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic mutagenesis of EpoR and KIT tyrosines with functional readouts, single lab\",\n      \"pmids\": [\"18538998\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PFCP-associated EPOR mutations (deletion Del1377-1411, nonsense C1370A, missense G1445A) cause slower receptor degradation, higher levels of glycan-mature receptor forms, increased sensitivity to low ligand concentrations, and extended downstream signaling cascades, as studied using EGFR–EPOR chimeric receptors. These mechanisms explain Epo hypersensitivity in PFCP patients.\",\n      \"method\": \"EGFR–EPOR chimeric receptor system activated by EGF binding, Western blot for receptor glycosylation/degradation, signaling duration assays\",\n      \"journal\": \"British journal of haematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — chimeric receptor system with defined mutations, multiple biochemical readouts, single lab\",\n      \"pmids\": [\"24533580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"EpoR in osteoprogenitor cells (EpoR:Osx-cre conditional knockout) is required for normal bone homeostasis and for EPO-induced bone loss. Deletion of EpoR in osteoprogenitors reduced the RANKL/OPG ratio, decreased osteoblast-supported osteoclastogenesis, and protected female mice from EPO-induced trabecular bone loss and increased osteoclast numbers. This demonstrates that EpoR in osteoprogenitors regulates osteoblast function and osteoblast-mediated osteoclastogenesis.\",\n      \"method\": \"EpoR:Osx-cre conditional knockout mice, histomorphometry, serum bone markers (P1NP, osteocalcin, TRAP), osteoblast/osteoclast co-culture from cKO vs. control, EPO pump implantation\",\n      \"journal\": \"Bone research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional genetic deletion with multiple in vivo and ex vivo readouts, co-culture mechanistic validation, and rescue by EPO challenge in a single rigorous study\",\n      \"pmids\": [\"34518518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"SFFV gp52 env protein forms an immunoprecipitable complex with EpoR in the endoplasmic reticulum. However, formation of this ER complex is not sufficient for either mitogenicity in cell culture or pathogenicity in mice; instead, processing of gp52 to more highly glycosylated forms is required for EpoR-dependent mitogenicity and splenomegaly.\",\n      \"method\": \"Glycosylation site mutants of SFFV env, co-immunoprecipitation of gp52 with EpoR, BaF3-epoR cell mitogenicity assays, mouse splenomegaly model\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus mutagenesis plus functional and in vivo assays, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"8437218\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Six monoclonal antibodies (MoAbs) to the extracellular domain of human EpoR were generated. Four neutralizing (Group I) MoAbs compete with radiolabeled EPO for EpoR binding and inhibit EPO-dependent cell growth, identifying the EPO-binding epitope region. Two non-neutralizing MoAbs recognize discrete epitopes that do not overlap the EPO-binding site.\",\n      \"method\": \"Monoclonal antibody generation, immunoprecipitation of 35S-labeled EpoR, radiolabeled EPO competition binding assay, EPO-dependent Ba/F3-hEPO-R growth inhibition\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — competition binding plus functional neutralization assays, single lab defining ligand-binding epitope\",\n      \"pmids\": [\"7686789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"EPOR undergoes sharply ligand-dependent inward trafficking in UT7epo cells and primary proerythroblasts. EPOR-68K is a core-glycosylated intracellular pool and EPOR-70K comprises the apparent cell-surface EPOR population. Polycythemia-associated C-terminal truncated EPOR-T alleles are persistently activated upon EPO challenge, become over-represented during exponential growth, and result in EPO dose-dependent loss of endogenous wild-type EPOR through squelching of C-terminal-mediated negative feedback.\",\n      \"method\": \"Novel rabbit monoclonal antibodies to intracellular, phospho-activated, and extracellular EPOR domains; Brefeldin A treatment; N-glycanase digestion; Western blot analysis of EPOR forms; UT7epo and primary proerythroblast trafficking assays; expression of PFCP EPOR-T mutants\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal biochemical methods with validated reagents, single lab\",\n      \"pmids\": [\"22253704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"EpoR is expressed in erythroblastic island (EBI) macrophages (defined by tdTomato reporter in EpoR-tdTomato-Cre mice), as well as in subsets of hematopoietic stem cells, progenitors, megakaryocytes, B cells, spleen red pulp macrophages, and liver Kupffer cells. EPO injection selectively promotes proliferation of EpoR-expressing cells and induces erythroid lineage bias in hematopoiesis.\",\n      \"method\": \"EpoR-tdTomato-Cre knock-in reporter mouse, Cre-mediated floxed STOP excision validation, flow cytometry, EPO injection experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic reporter mouse with Cre-mediated validation plus functional EPO injection experiments, single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"34098576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"EpoR signaling in the monocytic/osteoclast lineage contributes to EPO-induced bone loss. Conditional deletion of EPOR in the monocytic lineage using LysMCre significantly reduced the high-dose EPO-induced increase in bone marrow preosteoclasts (CD115+) and the resulting trabecular bone loss in female mice, without interfering with erythropoiesis.\",\n      \"method\": \"LysMCre EPOR conditional knockout mice, Cx3cr1Cre EPOR conditional knockout mice, high- and low-dose EPO administration, flow cytometry for CD115+ preosteoclasts, microCT bone volume measurements\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two independent Cre-driver conditional KO models, in vivo EPO challenge, single lab\",\n      \"pmids\": [\"36233351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"EpoR activation leads to immediate Jak2-dependent phosphorylation of the CDK inhibitor p27Kip1 at tyrosine 88 (Y88), converting it from a CDK inhibitor to an activator/assembly factor of CDK4/6, thereby promoting erythroid progenitor proliferation. Knock-in mice with p27Y88F mutation exhibit lower red blood cell counts, lower hematocrit, and reduced CFU-E colony outgrowth.\",\n      \"method\": \"Co-immunoprecipitation of p27 with EpoR, p27-Y88 phosphorylation assays in presence of Jak2 inhibitor, p27Y88F knock-in mice, CFU-E colony assays, complete blood count analysis\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct binding assay, site-specific phosphorylation with Jak2 inhibitor validation, and in vivo knock-in genetic model with defined erythroid phenotype\",\n      \"pmids\": [\"37443738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"EPO regulates energy metabolism through the EPO-EpoR-RUNX1 axis. EpoR in white adipose tissue mediates metabolic activity; male mice with adipose-specific EpoR ablation show increased fat mass and obesity susceptibility. EPO treatment increases RUNX1 protein in adipose tissue by decreasing FBXW7 ubiquitin ligase expression, thereby stabilizing RUNX1, which directly inhibits lipogenic gene expression. This effect is absent in adipose-specific EpoR knockout mice.\",\n      \"method\": \"Adipose-specific EpoR knockout mice, EPO treatment of wild-type vs. knockout mice, RUNX1 protein stability assays, FBXW7 expression analysis, lipogenic gene expression profiling\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — tissue-specific conditional KO plus mechanistic dissection of FBXW7-RUNX1 axis, multiple in vivo and molecular readouts in single rigorous study\",\n      \"pmids\": [\"39284834\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"A truncated form of human EPO receptor (EPOR-T) acts as a dominant negative regulator of EPO-induced erythroid differentiation. EPOR-T transfection in UT-7/GM cells induces apoptosis in the presence of EPO and blocks EPO-induced erythroid differentiation and hemoglobinization. EPOR-T is expressed in 7/9 myelodysplastic syndrome cases but not in normal controls, suggesting it may contribute to ineffective erythropoiesis in MDS.\",\n      \"method\": \"Stable transfection of EPOR-T in UT-7/GM cells, EPO-dependent hemoglobinization assay, apoptosis assay, RT-PCR in MDS patient samples\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional transfection with apoptosis and differentiation readouts plus patient sample analysis, single lab\",\n      \"pmids\": [\"10029161\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Extracellular CIRP (eCIRP) reduces macrophage surface EPOR levels by impairing Rab26, a member of the Ras family of small G proteins that controls EPOR transport to the cell surface. Impaired Rab26 reduces surface EPOR, which restrains EPOR-mediated M2 macrophage polarization. EPO treatment fails to promote M2 polarization in Rab26 knockout macrophages, establishing Rab26 as required for EPOR surface expression and downstream macrophage polarization signaling.\",\n      \"method\": \"Myeloid-specific EPOR-deficient mice, Rab26 knockout macrophages, eCIRP treatment, flow cytometry for surface EPOR, macrophage polarization assays, LPS-induced ALI model\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO models for both EPOR and Rab26 with functional rescue assays, single lab\",\n      \"pmids\": [\"34925338\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"EPOR is a cytokine receptor that, upon EPO binding, recruits and activates JAK2, leading to phosphorylation of specific intracellular tyrosines (including Y343, Y401, Y429, Y431, Y479) that serve as docking sites for signaling adaptors (p85/PI3K, Grb2/Shp2, CIS) to activate STAT5, PI3K/AKT, and RAS/ERK pathways; STAT5 is the critical downstream effector for erythroid survival and differentiation (inducing Bcl-XL), while ligand-induced clathrin-mediated endocytosis terminates signaling through a p85 ubiquitination/Cbl/epsin-1 mechanism; truncating PFCP mutations in the EPOR C-terminus impair this endocytic negative feedback, causing Epo hypersensitivity; beyond erythropoiesis, EpoR is functionally expressed in osteoprogenitors, adipose tissue, macrophages, and other cell types where it regulates bone homeostasis, energy metabolism, and immune polarization through the same core JAK2/STAT pathway.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"EPOR is the erythropoietin receptor, a cytokine receptor that converts EPO binding into a JAK2-driven signaling program controlling erythroid progenitor survival, proliferation, and differentiation [#3, #9]. Upon stimulation, JAK2 phosphorylates EPOR cytoplasmic tyrosines that nucleate distinct effector arms: STAT5 activation is the critical downstream node for erythropoiesis, and constitutively active STAT5 alone rescues proliferation of both Jak2-/- and EpoR-/- cells, while Stat5-dependent induction of Bcl-XL prevents erythroblast apoptosis during terminal differentiation [#3, #9]. EPOR also drives Shc-independent Raf1/MEK/ERK activation via Shp2/Grb2 and a PI3K arm required for progenitor renewal [#7, #4]. Phosphorylated Y429/Y431/Y479 recruit the p85 subunit of PI3K, which—after Cbl-dependent ubiquitination and engagement of epsin-1—drives clathrin-mediated endocytosis that terminates signaling; C-terminal truncating mutations underlying primary familial and congenital polycythemia (PFCP) abolish p85 binding and internalization, causing EPO hypersensitivity and persistent receptor activation [#0, #1, #19, #23]. Signal magnitude is further constrained by a layered negative-feedback network including STAT5-induced SOCS/CIS proteins and Sprouty/Spred regulators that dampen JAK2 and ERK [#8, #16, #14, #13]. Beyond erythropoiesis, EpoR is functionally expressed and signals through the same axis in osteoprogenitors and the monocytic lineage to regulate bone homeostasis [#20, #25], in white adipose tissue via an EpoR-RUNX1 axis controlling energy metabolism [#27], and in macrophages where surface receptor levels gate M2 polarization [#29].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Defining the EPO-binding region of the receptor established which extracellular epitopes mediate ligand engagement and could neutralize signaling.\",\n      \"evidence\": \"Monoclonal antibodies against the human EpoR extracellular domain tested in EPO competition binding and growth-inhibition assays\",\n      \"pmids\": [\"7686789\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No atomic structure of the EPO-EPOR complex resolved here\", \"Does not address intracellular signal transduction\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Identifying a complex between SFFV gp52 env and EpoR showed the receptor can be aberrantly engaged, but processing—not mere binding—drives pathogenic mitogenesis.\",\n      \"evidence\": \"Co-immunoprecipitation of gp52 with EpoR plus glycosylation mutants in mitogenicity and splenomegaly assays\",\n      \"pmids\": [\"8437218\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of how processed gp52 activates EpoR not defined\", \"Relevance to physiological EPO signaling limited\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"EPO was shown to activate Raf1/ERK through Shp2/Grb2 rather than Shc, distinguishing the EpoR MAPK arm from other cytokine receptors.\",\n      \"evidence\": \"EPO/IL-2/IL-15 stimulation of CTLL-EPO-R cells with Shc/Shp2 immunoprecipitation and Raf1/ERK2 kinase assays\",\n      \"pmids\": [\"8978277\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor tyrosines responsible for Shp2/Grb2 recruitment not mapped here\", \"Single-lab biochemistry\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Replacing EpoR with the prolactin receptor in EpoR-/- progenitors established that EpoR provides a permissive, not instructive, signal for erythroid differentiation.\",\n      \"evidence\": \"Retroviral PrlR and PrlR/EpoR chimera transduction into EpoR-/- progenitors with prolactin/SCF differentiation assays\",\n      \"pmids\": [\"9716574\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not exclude EpoR-specific roles in non-erythroid tissues\", \"Quantitative signaling differences not measured\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"A truncated EPOR isoform acting as a dominant negative linked aberrant receptor forms to ineffective erythropoiesis in disease.\",\n      \"evidence\": \"Stable EPOR-T transfection in UT-7/GM cells with apoptosis/hemoglobinization assays and RT-PCR in MDS patient samples\",\n      \"pmids\": [\"10029161\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal role of EPOR-T in MDS pathogenesis not established\", \"Mechanism of dominant-negative interference not detailed\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Genetic and developmental studies placed EpoR signaling as both essential for progenitor renewal via PI3K and sufficient to advance the developmental switch to definitive erythropoiesis.\",\n      \"evidence\": \"p53-/- erythroid progenitor lines with STAT5/PI3K inhibition, and a constitutively active EpoR-R129C knock-in mouse\",\n      \"pmids\": [\"11439328\", \"11520789\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream PI3K effectors for renewal not defined\", \"How R129C accelerates the developmental switch mechanistically unclear\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Mapping SOCS/CIS induction to STAT5 established the negative-feedback layer that limits EPOR proliferative signaling.\",\n      \"evidence\": \"STAT5/MAPK/PI3K inhibition, EpoR mutant lines activating signaling subsets, and inducible SOCS overexpression with reporter assays\",\n      \"pmids\": [\"12396724\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor docking sites for individual SOCS proteins not all mapped\", \"Relative in vivo contribution of each SOCS not addressed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Two studies refined the EPOR cytoplasmic survival code—SLAP as a STAT5-inhibiting negative regulator and a tyrosine-independent membrane-proximal STAT5 survival signal.\",\n      \"evidence\": \"SLAP-EpoR co-IP and overexpression in erythroblasts; tyrosine-null EPOR mutants with dominant-negative STAT5 in 32D cells\",\n      \"pmids\": [\"12946994\", \"14662339\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How non-tyrosine sequences couple to STAT5 unresolved\", \"SLAP interaction surface on EpoR not mapped\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Genetic dissection established cell-autonomous requirements for EpoR, STAT5, and GR in erythroblast renewal and pinned terminal-differentiation survival on STAT5-driven Bcl-XL.\",\n      \"evidence\": \"Primary erythroblasts from EpoR-H, GRdim, and Stat5ab-/- mice with retroviral Bcl-XL rescue\",\n      \"pmids\": [\"16407844\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Integration of GR with EpoR/STAT5 signaling not molecularly defined\", \"Targets beyond Bcl-XL not enumerated\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"EPOR signaling was extended beyond the marrow to hepatic iron regulation via C/EBPalpha-dependent hepcidin suppression, and to KIT co-signaling through Y343.\",\n      \"evidence\": \"Anti-EPOR blocking antibody and C/EBPalpha ChIP in hepatocytes; KIT/EpoR tyrosine-to-phenylalanine mutants in 32D proliferation assays\",\n      \"pmids\": [\"18326822\", \"18538998\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional mechanism linking EpoR to C/EBPalpha not resolved\", \"In vivo relevance of KIT-EpoR Y343 cooperativity not tested genetically\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Constitutively active STAT5 rescuing both Jak2-/- and EpoR-/- erythroid cells placed STAT5 as the critical effector node downstream of the receptor.\",\n      \"evidence\": \"Genetic rescue with cS5 in KO fetal liver cells, tamoxifen-inducible Stat5a-ER, and fetal liver transplantation\",\n      \"pmids\": [\"18239084\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full STAT5 target program not defined here\", \"Roles of parallel PI3K/ERK arms not separated\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defining clathrin-mediated EPOR endocytosis via JAK2, Y429/Y431/Y479, and p85 recruitment established the signal-termination machinery and its failure in PFCP.\",\n      \"evidence\": \"EpoR tyrosine mutagenesis, p85alpha/beta knockdown and dominant negatives, clathrin inhibition, and PFCP mutant analysis\",\n      \"pmids\": [\"19336760\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"p85's PI3K-independent endocytic adaptor mechanism not fully detailed\", \"Kinetics of receptor recycling vs. degradation not resolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Multiple studies clarified EPOR trafficking, the molecular forms of the receptor, transcriptome targets, Spry1-mediated feedback, EpoR-independent JAK2V617F adhesion signaling, and EpoR control of red cell size.\",\n      \"evidence\": \"Domain-specific antibodies with N-glycanase/BFA; CFU-e transcriptome with Tnfr-sf13c validation; Mx1-Cre Spry1 deletion with LC-MS/MS PY53 discovery; EpoR knockdown in HEL cells; EpoR-/- and in vivo MCV measurements\",\n      \"pmids\": [\"22253704\", \"22808010\", \"22508938\", \"23160466\", \"34921133\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism coupling EpoR to MCV control not molecularly defined\", \"Spry1 target (Jak2 vs ERK) directness not fully separated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Cbl-dependent p85 ubiquitination engaging epsin-1 completed the endocytic mechanism and explained PFCP Epo hypersensitivity via lost negative feedback.\",\n      \"evidence\": \"Cbl knockdown/dominant negatives, epsin-1 UIM mutants, co-localization, and rescue of p85-binding in PFCP receptors\",\n      \"pmids\": [\"24113870\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase specificity for p85 vs receptor not fully resolved\", \"In vivo contribution to polycythemia not genetically tested here\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Chimeric-receptor analysis of PFCP mutants mechanistically linked C-terminal truncation to slower degradation, mature glycoforms, and extended signaling.\",\n      \"evidence\": \"EGFR-EPOR chimeras carrying PFCP deletions/nonsense/missense alleles with glycosylation, degradation, and signaling-duration readouts\",\n      \"pmids\": [\"24533580\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Chimeric system may not fully mimic native EPOR\", \"Quantitative contribution of each mutation to disease severity unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Mapping CIS to phospho-Y401 connected a specific receptor docking site to STAT5/ERK control and tumor suppression in JAK2V617F cells.\",\n      \"evidence\": \"CIS-EpoR co-IP at Y401, CIS RNAi/overexpression with SH2 mutants, STAT5/ERK assays, and nude mouse tumor formation\",\n      \"pmids\": [\"28038963\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect Y401-CIS binding not structurally confirmed\", \"In vivo erythroid relevance of CIS-Y401 not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"PTPN18 was identified as a JAK2-dependent EPO target phosphatase that sustains EPOR signaling and modulates receptor glycoforms and RHEX phosphorylation.\",\n      \"evidence\": \"Phospho-tyrosine PTM proteomics, PTPN18-Y389 mutagenesis, JAK2 inhibition, RHEX phospho-assays, and proliferation/survival readouts\",\n      \"pmids\": [\"32027948\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PTPN18 substrates not all defined\", \"In vivo erythroid role of PTPN18 untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Tissue-specific genetics and reporters revealed EpoR function and expression beyond erythroid cells—in osteoprogenitors regulating bone, in EBI macrophages and diverse hematopoietic subsets, and a Rab26-dependent surface-trafficking requirement for macrophage M2 polarization.\",\n      \"evidence\": \"EpoR:Osx-cre cKO with histomorphometry and osteoclast co-culture; EpoR-tdTomato-Cre reporter with EPO injection; myeloid EPOR-deficient and Rab26-KO macrophages with eCIRP and polarization assays\",\n      \"pmids\": [\"34518518\", \"34098576\", \"34925338\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether non-erythroid EpoR uses identical JAK2/STAT5 wiring not fully established\", \"Physiological ligand levels driving non-erythroid signaling unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Monocytic-lineage EPOR deletion showed EpoR signaling in osteoclast precursors mediates EPO-induced bone loss independently of erythropoiesis.\",\n      \"evidence\": \"LysMCre and Cx3cr1Cre EPOR cKO mice with EPO challenge, CD115+ preosteoclast flow cytometry, and microCT\",\n      \"pmids\": [\"36233351\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream effectors in osteoclast precursors not mapped\", \"Sex-specific effects not mechanistically explained\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"EpoR-driven JAK2 phosphorylation of p27Kip1 at Y88 was shown to convert p27 from CDK inhibitor to activator, providing a proliferative mechanism with an in vivo erythroid phenotype.\",\n      \"evidence\": \"p27-EpoR co-IP, Y88 phosphorylation with JAK2 inhibitor, p27Y88F knock-in mice, and CFU-E/CBC analysis\",\n      \"pmids\": [\"37443738\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether p27Y88 phosphorylation is direct by JAK2 not fully resolved\", \"Contribution relative to STAT5-driven proliferation unquantified\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"An EPO-EpoR-RUNX1 axis in white adipose tissue was defined, where EPO stabilizes RUNX1 by lowering FBXW7 to suppress lipogenesis and control energy metabolism.\",\n      \"evidence\": \"Adipose-specific EpoR-KO mice with EPO treatment, RUNX1 stability and FBXW7 expression assays, and lipogenic gene profiling\",\n      \"pmids\": [\"39284834\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling steps from EpoR to FBXW7 regulation not defined\", \"Sex-specific (male) phenotype mechanism unexplained\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Whether non-erythroid EpoR functions (bone, adipose, macrophage) employ the same JAK2/STAT5/PI3K/ERK wiring and receptor tyrosines as erythroid signaling remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No tissue-by-tissue mapping of EpoR tyrosine usage\", \"Endogenous ligand and dosage driving non-erythroid signaling unclear\", \"No structural model of full-length receptor signaling complexes in the corpus\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [3, 9, 7]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [22, 0]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [8, 16, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 23, 29]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [21, 23]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [0, 1, 23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 7, 0]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [24, 29, 25]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [0, 1, 23]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [5, 20]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"JAK2\", \"STAT5A\", \"PIK3R1\", \"CBL\", \"CISH\", \"SLA\", \"KIT\", \"CDKN1B\"],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}